Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where V R Babu is active.

Publication


Featured researches published by V R Babu.


International Journal of Gynecology & Obstetrics | 1991

Establishment and characterization of UM-EC-2, a tamoxifen-sensitive, estrogen receptor-negative human endometrial carcinoma cell line

Seija E. Grenman; Maria J. Worsham; D. L. Van Dyke; Barry G. England; Kenneth D. McClatchey; V R Babu; James A. Roberts; Juhani Mäenpää; Thomas E. Carey

UM-EC-2 was established from a patient with poorly differentiated stage IB endometrial carcinoma. This cell line produces tumors in nude mice that have the same histological features as the patients tumor. UM-EC-2 cells express b2-microglobulin, the epidermal growth factor receptor (EGF), and the H blood group antigen. This membrane antigen phenotype is consistent with cells of human endometrial origin. The karyotype of UM-EC-2 is fairly complex, with rearrangements affecting all chromosomes except 3, 10, 14, 19, and 20. There were two populations of cells, a hyperdiploid population with a modal number of 53-55 and a hypertetraploid population with a modal number of 109. A postulated sequence of events before and after tetraploidization is suggested based on the number of copies of individual chromosomes and rearrangements. Comparison of the UM-EC-2 karyotype to that of UM-EC-1 (a previously described line from a different patient with endometrial carcinoma) revealed that the two lines share eight very similar chromosome changes, which include loss of most of chromosome 4, breakpoints affecting proximal bands on 8p, loss of most of 9q, a breakpoint at 12q22, loss of 13q, breakpoints in proximal bands on 18q, and a breakpoint at 22p11. These changes may represent nonrandom chromosome abnormalities in poorly differentiated endometrial cancer. Estrogen (ER) and progesterone (PgR) receptors were not detected in either the primary tumor or the cell line. Nevertheless, UM-EC-2 cells were very sensitive to growth inhibition by tamoxifen (TAM) in vitro. One micromolar TAM caused 50% inhibition of cell growth, 2.5 microM caused cytostasis, and 5 microM TAM was cytotoxic, killing all cells after 5-7 days of exposure to the drug. Paradoxically, 100 nM estradiol (E2) caused a moderate increase in the growth of the cells but it did not prevent or reverse growth inhibitory effects of TAM. These findings support the concept that in some tumors TAM causes growth inhibition by an ER-independent mechanism. UM-EC-2 cells were also sensitive to growth regulation by EGF. Thus, these cells provide a new in vitro model of human endometrial cancer in which the roles of both TAM and EGF as growth regulatory substances can be investigated.


American Journal of Human Genetics | 1990

The frequency of aneuploidy in cultured lymphocytes is correlated with age and gender but not with reproductive history

G P Nowinski; D. L. Van Dyke; Barbara C. Tilley; G Jacobsen; V R Babu; Maria J. Worsham; G N Wilson; Lester Weiss


American Journal of Human Genetics | 1983

The frequency and mutation rate of balanced autosomal rearrangements in man estimated from prenatal genetic studies for advanced maternal age.

Van Dyke Dl; Lester Weiss; Roberson; V R Babu


Cancer Research | 1987

Tumor Behavior in Transitional Cell Carcinoma of the Bladder in Relation to Chromosomal Markers and Histopathology

V R Babu; M.D. Lutz; Brian J. Miles; R. N. Farah; Lester Weiss; D. L. Van Dyke


Proceedings of the National Academy of Sciences of the United States of America | 1984

Chromosome 20 deletion in human multiple endocrine neoplasia types 2A and 2B: a double-blind study

V R Babu; D. L. Van Dyke; Charles E. Jackson


American Journal of Human Genetics | 1989

A dicentric recombinant 9 derived from a paracentric inversion: phenotype, cytogenetics, and molecular analysis of centromeres.

Maria J. Worsham; D A Miller; J M Devries; A R Mitchell; V R Babu; V Surli; Lester Weiss; D. L. Van Dyke


American Journal of Human Genetics | 1986

A practical metaphase marker of the inactive X chromosome

D. L. Van Dyke; W L Flejter; Maria J. Worsham; Jacquelyn Roberson; James V. Higgins; H M Herr; S Knuutila; Nancy Wang; V R Babu; Lester Weiss


Henry Ford Hospital medical journal | 1988

Duplication and deletion 11q23-q24 recombinants in two offspring of an intrachromosomal insertion ('shift') carrier

Forsythe Mg; Walker H; Lester Weiss; Roberson; Worsham Mj; V R Babu; Van Dyke Dl


Cancer Genetics and Cytogenetics | 1989

A prospective study of 92 bladder cancer patients: Cytogenetics, histopathology, and tumor behavior

V R Babu; Brian J. Miles; J.C. Cerney; J.D. Crissman; T. Drumheller; Lester Weiss; D.L. Van Dyke


Henry Ford Hospital medical journal | 1984

Chromosomes in multiple endocrine neoplasia type 2 syndromes

Van Dyke Dl; V R Babu; Jackson Ce

Collaboration


Dive into the V R Babu's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Van Dyke Dl

Henry Ford Health System

View shared research outputs
Top Co-Authors

Avatar

M.D. Lutz

Henry Ford Health System

View shared research outputs
Top Co-Authors

Avatar

Roberson

Henry Ford Health System

View shared research outputs
Top Co-Authors

Avatar

A R Mitchell

Henry Ford Health System

View shared research outputs
Top Co-Authors

Avatar

B. K S Raman

Henry Ford Health System

View shared research outputs
Top Co-Authors

Avatar

Barbara C. Tilley

University of Texas Health Science Center at Houston

View shared research outputs
Researchain Logo
Decentralizing Knowledge